BCL2 and MCL1 inhibitors for hematologic malignancies

Roberts, AW; Wei, AH; Huang, DCS

Author(s): Roberts, AW; Wei, AH; Huang, DCS;
Details: Publication Year 2021-09-30,Volume 138,Issue #13,Page 1120-1136
Journal Title: Blood
Abstract: BCL2 and MCL1 are commonly expressed prosurvival (antiapoptotic) proteins in hematologic cancers and play important roles in their biology either through dysregulation or by virtue of intrinsic importance to the cell-of-origin of the malignancy. A new class of small-molecule anticancer drugs, BH3 mimetics, now enable specific targeting of these proteins in patients. BH3 mimetics act by inhibiting the prosurvival BCL2 proteins to enable the activation of BAX and BAK, apoptosis effectors that permeabilize the outer mitochondrial membrane, triggering apoptosis directly in many cells and sensitizing others to cell death when combined with other antineoplastic drugs. Venetoclax, a specific inhibitor of BCL2, is the first approved in class, demonstrating striking single agent activity in chronic lymphocytic leukemia and in other lymphoid neoplasms, as well as activity against acute myeloid leukemia (AML), especially when used in combination. Key insights from the venetoclax experience include that responses occur rapidly, with major activity as monotherapy proving to be the best indicator for success in combination regimens. This emphasizes the importance of adequate single-agent studies for drugs in this class. Furthermore, secondary resistance is common with long-term exposure and often mediated by genetic or adaptive changes in the apoptotic pathway, suggesting that BH3 mimetics are better suited to limited duration, rather than continuous, therapy. The success of venetoclax has inspired development of BH3 mimetics targeting MCL1. Despite promising preclinical activity against MYC-driven lymphomas, myeloma, and AML, their success may particularly depend on their tolerability profile given physiological roles for MCL1 in several nonhematologic tissues.
Publisher: Elsevier
Keywords: Animals; Antineoplastic Agents/pharmacology/*therapeutic use; Apoptosis/drug effects; Drug Discovery; Hematologic Neoplasms/*drug therapy/metabolism; Humans; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein/*antagonists & inhibitors/metabolism; Proto-Oncogene Proteins c-bcl-2/*antagonists & inhibitors/metabolism
Research Division(s): Blood Cells And Blood Cancer
PubMed ID: 34320168
Publisher's Version: https://doi.org/10.1182/blood.2020006785
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2022-03-04 01:43:21

Last Modified: 2022-03-04 01:55:36